MiMedx Group (NASDAQ:MDXG) Sets New 12-Month Low – Here’s Why

MiMedx Group, Inc (NASDAQ:MDXG)’s share price hit a new 52-week low during trading on Friday . The company traded as low as $4.80 and last traded at $4.94, with a volume of 2595097 shares traded. The stock had previously closed at $5.28.

MiMedx Group News Roundup

Here are the key news stories impacting MiMedx Group this week:

• Positive Sentiment: Q4 beats — MiMedx reported Q4 EPS of $0.14 (vs. $0.09 consensus) and revenue of ~$118.1M (vs. ~$106.8M consensus), showing healthy top‑ and bottom‑line beats and margin expansion. MiMedx Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Record results and capital return — The company called Q4 and full‑year 2025 results “record,” reported $29M adjusted EBITDA for the quarter, and announced a $100M share repurchase authorization, which supports shareholder value. GlobeNewswire Press Release
• Neutral Sentiment: Earnings call available — Management discussed surgical growth initiatives and reimbursement dynamics on the call; investors can listen to the transcript for detail on execution plans and timing. MiMedx Q4 2025 Earnings Call Transcript
• Neutral Sentiment: New analyst coverage started — Citizens JMP began coverage (coverage initiation may add visibility but its rating/price target will determine impact). Citizens JMP Begins Coverage
• Negative Sentiment: Guidance below consensus and reimbursement uncertainty — Management guided FY‑2026 revenue to $340M–$360M, below the ~ $375M street estimate, and highlighted navigating reimbursement changes; the guidance shortfall and policy uncertainty are the primary bearish catalysts. MiMedx targets $340M–$360M 2026 revenue
• Negative Sentiment: Market reaction — Heavy intraday volume and the stock trading near its 52‑week low suggest investors are selling into the guidance/uncertainty despite the quarter’s beats and buyback announcement. Company Press Release / Financials

Analyst Upgrades and Downgrades

MDXG has been the topic of several recent analyst reports. Mizuho cut their target price on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 17th. Lake Street Capital cut their price target on shares of MiMedx Group from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 20th. Citigroup initiated coverage on shares of MiMedx Group in a research note on Monday. They set a “market outperform” rating for the company. Cantor Fitzgerald dropped their target price on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of MiMedx Group in a report on Monday, December 29th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.60.

MiMedx Group Stock Down 6.4%

The company’s fifty day simple moving average is $5.74 and its 200 day simple moving average is $6.59. The company has a current ratio of 4.41, a quick ratio of 3.95 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $731.61 million, a P/E ratio of 15.44 and a beta of 1.59.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.05. MiMedx Group had a net margin of 11.60% and a return on equity of 30.61%. The company had revenue of $118.10 million for the quarter, compared to analysts’ expectations of $106.78 million. Research analysts expect that MiMedx Group, Inc will post 0.3 EPS for the current year.

Hedge Funds Weigh In On MiMedx Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDXG. CWM LLC grew its position in shares of MiMedx Group by 63.8% in the 2nd quarter. CWM LLC now owns 4,857 shares of the company’s stock worth $30,000 after buying an additional 1,892 shares during the period. PNC Financial Services Group Inc. grew its holdings in MiMedx Group by 1,808.4% in the second quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after purchasing an additional 7,107 shares during the period. Kemnay Advisory Services Inc. bought a new position in shares of MiMedx Group during the fourth quarter valued at approximately $48,000. State of Alaska Department of Revenue purchased a new position in shares of MiMedx Group during the third quarter valued at approximately $54,000. Finally, Headlands Technologies LLC bought a new stake in shares of MiMedx Group in the 2nd quarter worth approximately $72,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.